AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12085418
Drug: Losartan/Hydrochlorothiazide 20/12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan/Hydrochlorothiazide 20/12.5 mg/day (LH)
Trial: 9593032
Drug: Trivalent cold-adapted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent cold-adapted influenza vaccine (CAIV-T) at high dose
Trial: 9593032
Drug: Trivalent cold-adapted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent cold-adapted influenza vaccine (CAIV-T) at low dose
Trial: 9593032
Drug: Trivalent cold-adapted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent cold-adapted influenza vaccine (CAIV-T) administered by drops
Trial: 9593032
Drug: Trivalent cold-adapted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent cold-adapted influenza vaccine (CAIV-T) administered by spray
Trial: 7551834
Drug: Control (ECOG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (ECOG chemotherapy protocols)
Trial: 2230272
Drug: Selective decontamination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective decontamination (polymyxin, gentamicin, and nystatin as oral paste and solution)
Trial: 31959235
Drug: MS Stay
RxNorm normalized name: MS-1819
DrugBank: MS-1819 (DB15004)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MS Stay Fit (two booster sessions at 2 and 4 months after end of treatment)
Trial: 28556449
Drug: 2.4 mg
RxNorm normalized name: pectin 2.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 mg beloranib
Trial: 17195608
Drug: Interventional management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interventional management (medical treatment, early coronarography, revascularization)
Trial: 14624703
Drug: Baclofen (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen (60 mg/day)
Trial: 7523739
Drug: Methotrexate (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (50 mg/m²) + Misoprostol (800 mcg)
Trial: 7523739
Drug: Misoprostol (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (800 mcg) alone
Trial: 3366415
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg dose of trans-anethole
Trial: 3366415
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg dose of trans-anethole
Trial: 3366415
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg dose of trans-anethole
Trial: 25286691
Drug: Injectable cefetamet
RxNorm normalized name: cefetamet
DrugBank: Cefetamet (DB13504)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable cefetamet sodium (500 mg, 1,000 mg, 2,000 mg)
Trial: 25286691
Drug: Injectable cefetamet
RxNorm normalized name: cefetamet
DrugBank: Cefetamet (DB13504)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable cefetamet sodium (500 mg)
Trial: 25286691
Drug: Injectable cefetamet
RxNorm normalized name: cefetamet
DrugBank: Cefetamet (DB13504)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable cefetamet sodium (1,000 mg)
Trial: 25286691
Drug: Injectable cefetamet
RxNorm normalized name: cefetamet
DrugBank: Cefetamet (DB13504)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable cefetamet sodium (2,000 mg)
Trial: 19298635
Drug: Budesonide 200
RxNorm normalized name: budesonide 200 mcg/inh inhalation powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 200 μg once daily in the morning
Trial: 18199095
Drug: Intravenous L-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous L-carnitine supplementation
Trial: 16050414
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II blockers
Trial: 16050414
Drug: Concomitant use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant use of statins and angiotensin II blockers
Trial: 11520725
Drug: Nasal oxygen
RxNorm normalized name: TUBE,NASAL OXYGEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal oxygen (2 L/min)
Trial: 7031982
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin fraction
Trial: 7031982
Drug: High molecular
RxNorm normalized name: dextran, high molecular weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High molecular weight heparin fraction
Trial: 7031982
Drug: All heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All heparin preparations
Trial: 25765966
Drug: Concomitant administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concomitant administration of ProQuad(®) and hexavalent vaccine
Trial: 25765966
Drug: Hexavalent vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexavalent vaccine alone
Trial: 11320361
Drug: Accelerated TPA
RxNorm normalized name: tPA
DrugBank: Phorbol 12-myristate 13-acetate diester (DB17045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated TPA with reduced heparin dose mid-trial
Trial: 11320361
Drug: Accelerated TPA
RxNorm normalized name: tPA
DrugBank: Phorbol 12-myristate 13-acetate diester (DB17045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated TPA with lowest heparin dose
Trial: 11320361
Drug: Single-bolus TNK-TPA
RxNorm normalized name: TNK-tPA
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-bolus TNK-TPA and lanoteplase with reduced heparin dose
Trial: 11320361
Drug: Lower-dose, weight-adjusted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-dose, weight-adjusted heparin regimen (60 U/kg bolus; maximum, 4000 U; 12 U/kg per hour infusion; maximum, 1000 U/h)
Trial: 9447478
Drug: Thiothixene (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiothixene (20 mg single oral dose)
Trial: 28902705
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin D (120,000 IU/monthly)
Trial: 28902705
Drug: Moderate dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate dose vitamin D (60,000 IU/monthly)
Trial: 28902705
Drug: Standard/control dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard/control dose vitamin D (18,000 IU/monthly)
Trial: 26303780
Drug: MFGM (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MFGM (1 g)
Trial: 24030722
Drug: Campaign materials
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Campaign materials (mainly posters, brochures, and advertisements on local media, plus a newsletter on local antibiotic resistance targeted at doctors and pharmacists)
Trial: 21132310
Drug: Intracoronary pyruvate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary pyruvate (300 mmol/L, 360 ml/h)
Trial: 18300256
Drug: Docetaxel every
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel every 3 weeks (75 mg/m2)
Trial: 18300256
Drug: Docetaxel weekly
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel weekly (35 mg/m2)
Trial: 6532147
Drug: Alcohol (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.6 g of ethanol per kg of body weight)
Trial: 6532147
Drug: Non-alcohol treatments
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-alcohol treatments
Trial: 26285178
Drug: Mifepristone 200
RxNorm normalized name: mifepristone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 200 mg followed by misoprostol 800 mcg vaginally 6-8 or 23-25 hours later
Trial: 26285178
Drug: Mifepristone 200
RxNorm normalized name: mifepristone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 200 mg followed by misoprostol 800 mcg vaginally < 15 min or 23-25 hours later
Trial: 15653703
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate (HDMTX) 4 g/m² followed by leucovorin rescue
Trial: 7719244
Drug: Various biologic
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various biologic and chemotherapeutic agents for hairy-cell leukemia
Trial: 2692651
Drug: Weekly 20
RxNorm normalized name: buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly 20 mg doses of doxorubicin
Trial: 25440999
Drug: Telmisartan 40
RxNorm normalized name: telmisartan 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 40 mg orally once a day for 12 weeks
Trial: 25440999
Drug: Lisinopril 5
RxNorm normalized name: lisinopril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 5 mg orally once a day for 12 weeks
Trial: 25440999
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between telmisartan and lisinopril
Trial: 16500321
Drug: Cetrorelix (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetrorelix (0.25 mg SC) with half dose of recombinant FSH for 2 days until hCG administration
Trial: 16500321
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (n = 32) continued recombinant FSH until hCG administration
Trial: 12795584
Drug: Behavioral day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral day treatment plus abstinence-contingent housing and work therapy
Trial: 12795584
Drug: Behavioral day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral day treatment only
Trial: 10856892
Drug: Intravenous TRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous TRH administration
Trial: 10856892
Drug: Nasal TRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal TRH administration
Trial: 10856892
Drug: Oral TRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral TRH administration
Trial: 9168167
Drug: Clonazepam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonazepam (1 mg for 1 day)
Trial: 9168167
Drug: Vigabatrin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigabatrin (1000 mg per day for 5 days)
Trial: 3510282
Drug: Continuous cyclic
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous cyclic therapy with dibromodulcitol, doxorubicin, vincristine, tamoxifen, and fluoxymesterone (DAVTH)
Trial: 3510282
Drug: Serial CEA
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serial CEA levels during therapy
Trial: 3510282
Drug: Continuous DAVTH
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous DAVTH therapy
Trial: 24884602
Drug: Canakinumab low
RxNorm normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Canakinumab low dose (0.03 mg/kg i.v. once, N = 20)
Trial: 24884602
Drug: Canakinumab intermediate
RxNorm normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Canakinumab intermediate dose (0.1 and 0.3 mg/kg i.v. once, 5 and 15 mg s.c. monthly, N = 247)
Trial: 24884602
Drug: Canakinumab medium
RxNorm normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Canakinumab medium dose (1.5 mg/kg i.v. once, 50 mg s.c. monthly and 150 mg s.c. once, N = 268)
Trial: 24884602
Drug: Canakinumab high
RxNorm normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Canakinumab high dose (10 mg/kg i.v. once and 150 mg s.c. monthly, N = 137)
Trial: 23102995
Drug: Olmesartan plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan plus Calcium Channel Blocker (CCB)
Trial: 23102995
Drug: Olmesartan plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan plus Diuretic
Trial: 1828408
Drug: Esaprazole (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esaprazole (450 mg bid)
Trial: 1828408
Drug: Sulglicotide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulglicotide (200 mg tid)
Trial: 7014284
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg i.m. domperidone
Trial: 7014284
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg t.i.d. domperidone
Trial: 28389389
Drug: Capsaicin nasal
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsaicin nasal spray
Trial: 26010860
Drug: Paroxetine 20mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 20mg/day for 6 weeks, with dose escalation up to 50mg/day for non-responders
Trial: 21300339
Drug: Depot leuprolide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depot leuprolide, 11.25 mg IM every 12 weeks with hormonal add-back using norethindrone acetate 5 mg orally, daily
Trial: 21300339
Drug: Generic monophasic
RxNorm normalized name: Monobasic Potassium Phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic monophasic oral contraceptive (1 mg norethindrone + 35 mg ethinyl estradiol) given daily
Trial: 11416677
Drug: candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: candesartan cilexetil 16 mg once daily, increased to 32 mg after 2 weeks
Trial: 11416677
Drug: losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: losartan 50 mg once daily, increased to 100 mg after 2 weeks
Trial: 9293650
Drug: 30 ml
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml of 0.125% bupivacaine (with 1/200,000 epinephrine)
Trial: 9293650
Drug: 30 ml
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml of isotonic saline (with 1/200,000 epinephrine)
Trial: 8447520
Drug: Low clearing
RxNorm normalized name: Caladryl Clear
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low clearing doses of ivermectin followed by 200-400 micrograms/kg of ivermectin
Trial: 8447520
Drug: 6 or
RxNorm normalized name: Serc-16 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 or 7 mg/kg of DEC
Trial: 8447520
Drug: Clearing dose
RxNorm normalized name: Caladryl Clear
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clearing dose of ivermectin followed by 6 mg/kg of DEC
Trial: 3768248
Drug: Theophylline preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline preparation with ethylenediamine
Trial: 3768248
Drug: Theophylline preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline preparation with sodium glycinate
Trial: 29696963
Drug: Metoprolol (on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (on the basis of aspirin)
Trial: 23365129
Drug: Cinacalcet and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinacalcet and low-dose vitamin D sterols (Cin-D)
Trial: 23365129
Drug: Larger, varying
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Larger, varying doses of calcitriol or other vitamin D analogs (Flex-D)
Trial: 20601929
Drug: Expedited partner
RxNorm normalized name: Milkthistle Fruit (Silybum Marianum L. Gaertner)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expedited partner therapy (EPT)
Trial: 16422889
Drug: Testosterone patch
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone patch (5 mg/day applied at 2200 h)
Trial: 16422889
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel (5 g/day applied at 0800 h)
Trial: 12835492
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (30 mg/d) for 14 weeks followed by copper supplementation (3 mg/d) for 8 weeks
Trial: 12835492
Drug: Placebo supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo supplements for the full duration of the trial
Trial: 1387041
Drug: Oral terfenadine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral terfenadine (120 mg)
Trial: 1387041
Drug: Oral terfenadine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral terfenadine (120 mg) and nasal ipratropium bromide (80 micrograms)
Trial: 6437102
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg levonorgestrel per coitus
Trial: 6437102
Drug: 0.75 mg
RxNorm normalized name: propinox 0.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mg levonorgestrel per coitus
Trial: 6437102
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of levonorgestrel
Trial: 24670520
Drug: protease inhibitor+RTV+two
RxNorm normalized name: Protease inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: protease inhibitor+RTV+two NRTIs
Trial: 23158423
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (35 ml contrast medium)
Trial: 23158423
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (40 ml contrast medium)
Trial: 23158423
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C (45 ml contrast medium)
Trial: 23158423
Drug: Group D
RxNorm normalized name: Prostaglandin group D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group D (50 ml contrast medium)
Trial: 19022318
Drug: Low-dose intradermal
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intradermal injection (3 microg hemagglutinin per strain) using MicronJet (ID1 group)
Trial: 19022318
Drug: Medium-dose intradermal
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose intradermal injection (6 microg hemagglutinin per strain) using MicronJet (ID2 group)
Trial: 19022318
Drug: Full-dose standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose standard flu shot (15 microg hemagglutinin per strain) delivered intramuscularly (IM group)
Trial: 2574193
Drug: Diazepam (N
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (N = 21; mean diazepam dose equivalents, 15 mg/day; range, 5‐40)
Trial: 28665371
Drug: mexidol: 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mexidol: 500 mg/day IV infusion for 10 days, followed by 125 mg tid (375 mg/day) PO for 8 weeks
Trial: 23457387
Drug: Golimumab (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Golimumab (combined 50 mg + MTX or 100 mg ± MTX), n = 115
Trial: 12117291
Drug: Heparin rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin rinse at 2,000 IU/L
Trial: 12117291
Drug: Heparin rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin rinse at 10,000 IU/L
Trial: 30898822
Drug: Belimumab SC
RxNorm normalized name: Belimumab
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Belimumab SC 200 mg/week for 52 weeks plus placebo at weeks 4 and 6
Trial: 30898822
Drug: Belimumab SC
RxNorm normalized name: Belimumab
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Belimumab SC 200 mg/week for 52 weeks plus rituximab 1000 mg at weeks 4 and 6
Trial: 30898822
Drug: Belimumab SC
RxNorm normalized name: Belimumab
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Belimumab SC 200 mg/week plus standard of care for 104 weeks
Trial: 25477424
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg 6R‐BH4 twice daily + 1 mg folic acid once daily
Trial: 24147622
Drug: Deferasirox (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferasirox (20 mg/kg/day, titrated to 5-10 mg/kg/day based on serum ferritin trends)
Trial: 24147622
Drug: Deferasirox (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferasirox (mean actual dose 33.6 mg/kg/day in 1-year extension)
Trial: 19517675
Drug: Unilateral spinal
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral spinal anaesthesia (group B, n=27, 0.5% hyperbaric bupivacaine, 1.2 mL + 0.1 mL per every 10 cm over 170 cm height)
Trial: 19517675
Drug: Bilateral spinal
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral spinal anaesthesia (group K, n=27, 0.5% bupivacaine 2.4 mL + 0.2 mL per every 10 cm over 170 cm height)
Trial: 11287776
Drug: Pyridoxine 50
RxNorm normalized name: pyridoxine 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridoxine 50 mg/day
Trial: 7999470
Drug: Individual screening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual screening prescriptions based on risk
Trial: 24131167
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch + nicotine nasal spray
Trial: 24131167
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch + placebo nasal spray
Trial: 21112774
Drug: Chemoradiotherapy (CRT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiotherapy (CRT) with cisplatin (100mg/m(2) for three cycles) plus adjuvant cisplatin (80 mg/m(2)) and fluorouracil (1000 mg/m(2)/day for 4 days for three cycles)
Trial: 21112774
Drug: Cisplatin during
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin during concurrent phase